KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Shares (2018 - 2021)

Xenon Pharmaceuticals (XENE) has disclosed Preferred Shares for 6 consecutive years, with $7.7 million as the latest value for Q4 2021.

  • On a quarterly basis, Preferred Shares changed 0.0% to $7.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $7.7 million, a 0.0% change, with the full-year FY2021 number at $7.7 million, changed 0.0% from a year prior.
  • Preferred Shares was $7.7 million for Q4 2021 at Xenon Pharmaceuticals, roughly flat from $7.7 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $21.8 million in Q1 2018 to a low of $7.7 million in Q1 2019.
  • A 4-year average of $9.9 million and a median of $7.7 million in 2019 define the central range for Preferred Shares.
  • Peak YoY movement for Preferred Shares: tumbled 64.57% in 2019, then changed 0.0% in 2020.
  • Xenon Pharmaceuticals' Preferred Shares stood at $11.9 million in 2018, then tumbled by 35.2% to $7.7 million in 2019, then changed by 0.0% to $7.7 million in 2020, then changed by 0.0% to $7.7 million in 2021.
  • Per Business Quant, the three most recent readings for XENE's Preferred Shares are $7.7 million (Q4 2021), $7.7 million (Q3 2021), and $7.7 million (Q2 2021).